Business Context and Reporting Period
Company: BiomX Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2026 (Event Date); Signed March 19, 2026
Context: The filing reports the entry into a material definitive agreement involving an amendment to a previously issued warrant.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a warrant amendment.
Material Changes and Agreement Details
The Company amended a Warrant issued on December 26, 2025, to an investor in a private placement. The original warrant allowed the purchase of up to 3,300,000 shares of Common Stock. The March 13, 2026 amendment includes the following changes:
- Expiration Date: Extended to December 31, 2026.
- Exercise Price: Reduced from $2.00 per share to $1.00 per share.
- Cashless Exercise Formula: Revised to determine the number of issuable shares based on the lowest Volume Weighted Average Price (VWAP) of the five (5) trading days immediately preceding the exercise notice, rather than the VWAP of the single day immediately preceding the notice.
- Share Count: No proportional adjustment was made to the total number of shares issuable upon exercise.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release dated March 19, 2026, regarding the amendment and general business updates, but the text of the press release is not included in this summary. The filing explicitly states that the information in Item 7.01 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Risks and Contingencies: The filing does not disclose specific new risks or contingencies beyond the standard legal disclaimers regarding the warrant amendment terms.
Key Facts for Investor Verification
- Verify the impact of the reduced exercise price ($1.00) on potential dilution to existing shareholders.
- Confirm the specific terms of the cashless exercise formula change and its effect on the number of shares issued if the stock price is volatile.
- Review the full text of the Warrant Amendment (Exhibit 4.1) and the March 19, 2026 press release (Exhibit 99.1) for additional context not summarized here.
- Note that the filing does not provide updated financial performance data; refer to the most recent 10-K or 10-Q for financial health.